Behavioural Intervention
Enterra Therapy System for Gastroparesis
"This trial aims to see if a new programming strategy for the Enterra device can help improve symptoms and quality of life for people with gastroparesis. Participants will have the device implanted, be assigned
Incretin Mimetic
Holding vs. Continuing Incretin-Based Therapies for Type 2 Diabetes
This trial aims to see if stopping incretin-based therapy before endoscopy can reduce the chances of having too much food in the stomach. The main things they are looking at are: - The
Behavioural Intervention
Vagal Nerve Stimulation for Gastroparesis
"This trial involves studying the effects of vagal nerve stimulation on patients with a gastric electrical stimulation device and healthy volunteers. The study will measure the nerve action potentials and gastric hormone changes in response to auricular
Popular Filters
Trials for Type 2 Diabetes Patients
Procedure
G-POEM for Gastroparesis
This trial is testing a new procedure called G-POEM in patients whose gastroparesis doesn't get better with medication. The goal is to see if G-POEM helps these patients by making it easier for food to leave the stomach. G-POEM is a novel endoscopic technique developed to treat refractory gastroparesis, especially in patients who have not responded to other treatments like gastric electrical stimulators.
Thiazolidinedione
Pioglitazone for Gastroparesis
This trial is testing whether pioglitazone, a diabetes medication, can help adults with chronic nausea and vomiting due to gastroparesis. The medication works by reducing inflammation and improving insulin response, which might improve stomach function.
Trials for GP Patients
Procedure
G-POEM for Gastroparesis
This trial is testing a new procedure called G-POEM in patients whose gastroparesis doesn't get better with medication. The goal is to see if G-POEM helps these patients by making it easier for food to leave the stomach. G-POEM is a novel endoscopic technique developed to treat refractory gastroparesis, especially in patients who have not responded to other treatments like gastric electrical stimulators.
Thiazolidinedione
Pioglitazone for Gastroparesis
This trial is testing whether pioglitazone, a diabetes medication, can help adults with chronic nausea and vomiting due to gastroparesis. The medication works by reducing inflammation and improving insulin response, which might improve stomach function.
Trials With No Placebo
Thiazolidinedione
Pioglitazone for Gastroparesis
This trial is testing whether pioglitazone, a diabetes medication, can help adults with chronic nausea and vomiting due to gastroparesis. The medication works by reducing inflammation and improving insulin response, which might improve stomach function.
Vagus Nerve Stimulator
Vagal Nerve Stimulation for Indigestion and Gastroparesis
This trial tests a treatment that sends mild electrical pulses to the outer ear to help people with stomach issues like functional dyspepsia and gastroparesis. The goal is to see if this can improve communication between the brain and stomach and reduce symptoms. Gastric electrical stimulation (GES) has been proposed as an effective treatment option for patients with gastroparesis that does not respond to other treatments.
Behavioral Intervention
Cognitive Behavioral Therapy for Gastroparesis
This trial tests if Cognitive Behavioral Therapy (CBT) can help people with gastroparesis by reducing their pain and negative emotions. CBT involves talking through problems and practicing new ways to think and act. The study will measure changes in symptoms over time to see how effective it is.
View More Related Trials
Frequently Asked Questions
Introduction to diabetic gastroparesis
What are the top hospitals conducting diabetic gastroparesis research?
When it comes to cutting-edge clinical trials for diabetic gastroparesis, several top hospitals are leading the charge. In Boston, Massachusetts General Hospital is at the forefront with three ongoing trials dedicated to this condition and an impressive history of 13 completed trials. With their first recorded trial dating back to 2005, they have been exploring innovative treatment options for over a decade. Meanwhile, in Cleveland, the renowned Cleveland Clinic Foundation has also made significant contributions with three active trials and four completed studies since their inaugural diabetic gastroparesis trial in 2022.
Johns Hopkins Bayview Medical Center in Baltimore has likewise emerged as a prominent player in this field. They currently have three ongoing clinical trials for diabetic gastroparesis and have conducted ten previous studies since initiating their first trial in 2012. Additionally adding itself to this list is the University of Michigan in Ann Arbor where two active clinical tests are being carried out alongside five previously held investigations; theirs can be traced back only eight years ago until2013.
Lastly but not least, Mayo Clinic located in Rochester boasts two current diabetic gastroparesis clinical trials along with an impressive track record of eight prior ones that began backin2010.The collective efforts of these esteemed institutions demonstrate unwavering commitment towards understanding and finding solutions for diabetic gastroparesis—a condition characterized by delayed stomach emptying due to diabetes-related nerve damage—which affects countless individuals globally.
These hospitals serve as beacons of hope for those living with diabetic gastroparesis while representing medical progressions that impact lives far beyond their respective locations
Which are the best cities for diabetic gastroparesis clinical trials?
When it comes to diabetic gastroparesis clinical trials, several cities have emerged as hubs of research and development. Houston, Texas; Boston, Massachusetts; Miami, Florida; Baltimore, Maryland; and Little Rock, Arkansas are all actively conducting studies in this field. Each city offers a varying number of active trials focused on different investigational treatments such as CIN-102 Dose 1, Domperidone, Cognitive Behavioral Therapy, Transcutaneous Electroacupuncture, and Tradipitant. These cities serve as crucial centers for individuals with diabetic gastroparesis seeking participation in cutting-edge clinical trials that could potentially lead to improved management strategies for this condition.
Which are the top treatments for diabetic gastroparesis being explored in clinical trials?
Clinical trials for diabetic gastroparesis are currently exploring several promising treatments. One such treatment is the Atmo Motility Gas Capsule System, which is being tested in one active trial and marks its first listing in 2023. Another innovative approach under investigation is endoscopic per-oral pyloromyotomy (POP), with one active trial and initial listing in 2022. Additionally, researchers are studying EndoFLIP, a technique that has shown potential through two past trials and continues to be explored in one ongoing trial since its introduction in 2015. These advancements hold promise for improving the lives of individuals living with diabetic gastroparesis by addressing the challenges posed by this condition's delayed gastric emptying.
What are the most recent clinical trials for diabetic gastroparesis?
Recent clinical trials offer hope and potential breakthroughs for individuals suffering from diabetic gastroparesis. CIN-102 Dose 1, a Phase 2 trial that became available on 3/27/2023, seeks to address the challenges of this condition. Additionally, tradipitant and nimacimab have shown promise as potential treatments in their respective Phase 3 and Phase 2 trials conducted in previous years. Rifaximin also holds potential based on its Phase 2 trial results from June 2019. These innovative studies highlight the ongoing efforts to improve the lives of those affected by diabetic gastroparesis through cutting-edge research.
What diabetic gastroparesis clinical trials were recently completed?
Recently completed clinical trials have advanced the understanding and treatment of diabetic gastroparesis, a condition characterized by delayed stomach emptying in individuals with diabetes. In March 2022, Processa Pharmaceuticals concluded their trial investigating PCS12852 as a potential therapy for this debilitating disorder. Additionally, Neurogastrx, Inc.'s NG101 trial was successfully completed in August 2020. These significant milestones signify important progress in addressing the challenges faced by patients with diabetic gastroparesis and offer hope for improved management strategies moving forward.